Subjective effects of narcotic antagonists.
D000704:Analysis of Variance; D003061:Codeine / Q000494:pharmacology; D003496:Cyclazocine / Q000494:pharmacology; D011431:Dextropropoxyphene / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004644:Emotions / Q000187:drug effects*; D006801:Humans; D007977:Levallorphan / Q000494:pharmacology; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D009021:Morphine Dependence / Q000188:drug therapy; D009266:Nalbuphine / Q000494:pharmacology; D009269:Nalorphine / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology*; D010423:Pentazocine / Q000494:pharmacology; D010919:Placebos; D013375:Substance Withdrawal Syndrome / Q000139:chemically induced* / Q000188:drug therapy; D011795:Surveys and Questionnaires
D009292:Narcotic Antagonists; D010919:Placebos; D007977:Levallorphan; D008238:Lysergic Acid Diethylamide; D003496:Cyclazocine; D009266:Nalbuphine; D010423:Pentazocine; D011431:Dextropropoxyphene; D009269:Nalorphine; D003061:Codeine